Novazonics announced that it has signed a strategic cooperation agreement with BGI. The two parties will cooperate in the fields of reproductive genetics, tumor prevention and control, chronic disease management and infection prevention and control, and promote genomics from basic research to clinical medicine. The cooperation period is 5 years, from March 6, 2025 to March 5, 2030. The specific details of the cooperation will be subject to the signing of subsequent agreements. This cooperation is not expected to have a significant impact on the company's 2025 annual performance, and the impact on the company's future annual operating performance will depend on the specific cooperation situation in the future.